Skip to main content

Table 1 Characteristics of patients enrolled in the study

From: Oral probiotic and prevention of Pseudomonas aeruginosa infections: a randomized, double-blind, placebo-controlled pilot study in intensive care unit patients

Characteristic

Placebo group (n = 106)

Probiotic group (n = 102)

Age (years; median [range])

57 (18–80)

60 (18–91)

Sex (male/female)

81/25a

65/37a

SAPS II score (mean ± SD)

44.2 ± 15.3

44.6 ± 16.0

Stay (days; median [range])

13.5 (3–88)

14.0 (3–91)

Gastric tube (days; median [range])

11.0 (2–88)

12.0 (1–90)

Urinary tract catheter (days; median [range])

13.0 (3–88)

14.0 (2–90)

Tracheal intubation (nb/days; median [range])

100/9.0 (1–88)

96/12.0 (1–90)

Ventilatory assistance (nb/days; median [range])

103/13.0 (3–88)

99/14.0 (2–90)

Vascular catheter (nb/days; median [range])

105/14.0 (3–88)

100/14.5 (2–90)

Antibiotic treatment

105

101

Antipseudomonas drugs (n; ceftazidime and/or imipenem and/or ciprofloxacin)

43

55

Fluconazole (n)

26a

45a

  1. aP < 0.05. bThe total number is indicated for characteristic when different from 106 and 102 for the placebo and the probiotic group, respectively. SAPS, Simplified Acute Physiology Score; SD, standard deviation.